The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: A cohort study

Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
Annals of internal medicine (Impact Factor: 17.81). 08/2009; 151(2):73-84.
Source: PubMed


HIV-1 genotypic and phenotypic susceptibility testing (GPT) optimizes antiretroviral selection, but its effect on survival is unknown.
To evaluate the association between GPT and survival.
Cohort study.
10 U.S. HIV clinics.
2699 HIV-infected patients eligible for GPT (plasma HIV RNA level >1000 copies/mL) seen from 1999 through 2005.
Demographic characteristics, clinical factors, GPT use, all-cause mortality, and crude and adjusted hazard ratios (HRs) for the association of GPT with survival.
Patients were followed for a median of 3.3 years; 915 (34%) had GPT. Patients who had GPT had lower mortality rates than those who did not (2.0 vs. 2.7 deaths per 100 person-years). In standard Cox models, GPT was associated with improved survival (adjusted HR, 0.69 [95% CI, 0.51 to 0.94]; P = 0.017) after controlling for demographic characteristics, CD4+ cell count, HIV RNA level, and intensity of clinical follow-up. In subgroup analyses, GPT was associated with improved survival for the 2107 highly active antiretroviral therapy (HAART)-experienced patients (2.2 vs. 3.2 deaths per 100 person-years for patients who had GPT vs. those who did not have GPT; adjusted HR, 0.60 [CI, 0.43 to 0.82]; P = 0.002) and for the 921 triple antiretroviral class-experienced patients (2.1 vs. 3.1 deaths per 100 person-years; adjusted HR, 0.61 [CI 0.40 to 0.93]; P = 0.022). Marginal structural models supported associations between GPT and improved survival in the overall cohort (adjusted HR, 0.54; P = 0.001) and in the HAART-experienced group (adjusted HR, 0.56; P = 0.003).
Use of GPT was not randomized. Residual confounding may exist.
Use of GPT was independently associated with improved survival among HAART-experienced patients.
Centers for Disease Control and Prevention.

Download full-text


Available from: Carl Armon,
  • Source
    • "Hence, we believe that our dataset has the potential to identify subsets of SSc-ILD patients who may be more likely to benefit from immunosuppression. There is strong precedent for the use of this type of study design coupled with sophisticated statistical analysis that addresses issues of confounding to determine the effectiveness of medical interventions in situations where RCTs are not always feasible or available (Choi et al. 2002; Sterne et al. 2005; MacKenzie et al. 2006; Cotter et al. 2008; Palella et al. 2009). It is highly relevant to note that influential groups, including the National Institute for Clinical Excellence, the United Kingdom's drug approval body committed to basing drug approvals on the highest standards of evidence, have recently advocated in favour of well-designed and carefully analyzed and interpreted observational studies as appropriate substitutes for RCTs, in particular in rare diseases for which there is a serious lack of data and for which it may not be feasible to undertake RCTs (Rawlins 2008). "

    Journal of Cell Communication and Signaling 08/2012; 6(4). DOI:10.1007/s12079-012-0172-4
  • Source
    • "who experience virologic nonsuppression while on therapy. Available evidence suggests that adoption of such testing as routine would facilitate tailoring of more effective cART [29], reduce the likelihood of further resistance evolution, and ultimately augment cART-related reductions in HIV-related mortality [7] [8] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Little is known about temporal trends in frequencies of clinically relevant ARV resistance mutations in HIV strains from U.S. patients undergoing genotypic testing (GT) in routine HIV care. Methods. We analyzed cumulative frequency of HIV resistance among patients in the HIV Outpatient Study (HOPS) who, during 1999-2008 and while prescribed antiretrovirals, underwent GT with plasma HIV RNA >1,000 copies/mL. Exposure ≥4 months to each of three major antiretroviral classes (NRTI, NNRTI and PI) was defined as triple-class exposure (TCE). Results. 906 patients contributed 1,570 GT results. The annual frequency of any major resistance mutations decreased during 1999-2008 (88% to 79%, P = 0.05). Resistance to PIs decreased among PI-exposed patients (71% to 46%, P = 0.010) as exposure to ritonavir-boosted PIs increased (6% to 81%, P < 0.001). Non-significant declines were observed in resistance to NRTIs among NRTI-exposed (82% to 67%), and triple-class-resistance among TCE patients (66% to 41%), but not to NNRTIs among NNRTI-exposed. Conclusions. HIV resistance was common but declined in HIV isolates from subgroups of ARV-experienced HOPS patients during 1999-2008. Resistance to PIs among PI-exposed patients decreased, possibly due to increased representation of patients whose only PI exposures were to boosted PIs.
    AIDS research and treatment 03/2012; 2012(2090-1240):230290. DOI:10.1155/2012/230290
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hormonal contraceptives are used widely worldwide; their effect on HIV acquisition remains unresolved. We reanalyzed data from the Hormonal Contraception and HIV Study using marginal structural modeling to reduce selection bias due to time-dependent confounding. Replicating our original analysis closely, we found that depo-medroxyprogesterone acetate (DMPA) but not combined oral contraceptive (COC) was associated with increased HIV acquisition. Also, young (18-24 years) but not older women who used DMPA and COCs were at increased HIV risk.
    AIDS (London, England) 07/2010; 24(11):1778-81. DOI:10.1097/QAD.0b013e32833a2537 · 5.55 Impact Factor
Show more